TSWM
LGND icon

Tyler-Stone Wealth Management’s Ligand Pharmaceuticals LGND Stock Holding History

Tyler-Stone Wealth Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8
Closed -$1K – 887
2022
Q1 		$1K Hold
8
– – ﹤0.01% 797
2021
Q4 		$1K Buy
+8
New +$739 ﹤0.01% 872

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Tyler-Stone Wealth Management's LGND Position: Q2 2022 in Review

Tyler-Stone Wealth Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2022, closing a stake of 8 shares — an estimated $1K sold.

Tyler-Stone Wealth Management first reported a position in LGND in Q4 2021 and held it in 2 quarters. The position peaked at $1K in Q1 2022. 197 funds tracked by Wall St. Rank hold LGND as of Q2 2022.

  • Tyler-Stone Wealth Management reported no remaining Ligand Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Tyler-Stone Wealth Management sold 8 Ligand Pharmaceuticals shares in Q2 2022, an estimated $1K.
  • Tyler-Stone Wealth Management first reported a position in Ligand Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Tyler-Stone Wealth Management's Ligand Pharmaceuticals position peaked at $1K in Q1 2022.
  • 197 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2022.

Based on Tyler-Stone Wealth Management's 13F filing for Q2 2022, filed 11 Aug 2022.